NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free PRQR Stock Alerts $2.29 -0.09 (-3.78%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.23▼$2.4750-Day Range$1.89▼$2.5652-Week Range$1.11▼$3.29Volume109,180 shsAverage Volume204,533 shsMarket Capitalization$186.31 millionP/E RatioN/ADividend YieldN/APrice Target$3.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProQR Therapeutics alerts: Email Address ProQR Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.4% Upside$3.80 Price TargetShort InterestHealthy0.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector735th out of 939 stocksPharmaceutical Preparations Industry347th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.80, ProQR Therapeutics has a forecasted upside of 67.4% from its current price of $2.27.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.52% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 3.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 3.2 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PRQR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.65% of the stock of ProQR Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About ProQR Therapeutics Stock (NASDAQ:PRQR)ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Read More PRQR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRQR Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from BrokeragesMarch 26, 2024 | americanbankingnews.comContrasting ProQR Therapeutics (NASDAQ:PRQR) & Regen BioPharma (OTCMKTS:RGBP)March 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 19, 2024 | americanbankingnews.comStockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to HoldMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.February 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingJanuary 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialJanuary 19, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024January 19, 2024 | finance.yahoo.comProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024January 15, 2024 | finance.yahoo.comWhile institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the mostJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing PlatformJanuary 5, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing CollaborationJanuary 5, 2024 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and DatesJanuary 5, 2024 | finance.yahoo.comProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing CollaborationDecember 28, 2023 | finance.yahoo.comIs ProQR (PRQR) Stock a Solid Choice Right Now?December 9, 2023 | markets.businessinsider.comProQR’s Strategic Divestiture and Strong Financial Outlook Justify Buy RatingDecember 8, 2023 | finance.yahoo.comProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic AssetsNovember 21, 2023 | morningstar.comProQR Therapeutics NV PRQRNovember 9, 2023 | markets.businessinsider.comPositive Report for ProQR (PRQR) from Chardan CapitalNovember 9, 2023 | markets.businessinsider.comBuy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial PositionNovember 8, 2023 | msn.comChardan Capital Upgrades ProQR Therapeutics N.V (PRQR)See More Headlines Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today3/29/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees156Year FoundedN/APrice Target and Rating Average Stock Price Target$3.80 High Stock Price Target$5.00 Low Stock Price Target$1.80 Potential Upside/Downside+67.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,430,000.00 Net Margins-431.65% Pretax Margin-426.98% Return on Equity-56.71% Return on Assets-19.15% Debt Debt-to-Equity Ratio0.10 Current Ratio3.54 Quick Ratio3.54 Sales & Book Value Annual Sales$7.05 million Price / Sales26.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book4.13Miscellaneous Outstanding Shares81,360,000Free Float74,521,000Market Cap$184.69 million OptionableOptionable Beta0.20 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Domenico Valerio Ph.D. (Age 68)Founder & Independent Chairman of Supervisory Board Comp: $80.36kMr. Daniel Anton de Boer (Age 41)Founder, CEO & Member of Management Board Comp: $1.3MMr. Rene K. Beukema (Age 60)Chief Corporate Development Officer, General Counsel & Member of Management Board Comp: $993.69kDr. Gerard Platenburg (Age 60)Co-Founder & Chief Scientific Officer Comp: $23.89kMr. Jurriaan Dekkers (Age 48)Chief Financial Officer Ms. Sheila Sponselee (Age 40)Chief People & Operations Officer Ms. Sarah Cue KielyVice President of Investor Relations & Corporate CommunicationsMs. Sandra van der KolkJunior Financial ControllerMore ExecutivesKey CompetitorsRenovaroNASDAQ:RENBInventivaNASDAQ:IVARepare TherapeuticsNASDAQ:RPTXCapricor TherapeuticsNASDAQ:CAPRAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 34,904 shares on 2/26/2024Ownership: 0.043%Citadel Advisors LLCBought 1,600 shares on 2/15/2024Ownership: 0.000%BNP Paribas Financial MarketsBought 9,200 shares on 2/7/2024Ownership: 0.020%Simplex Trading LLCSold 6,500 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions PRQR Stock Analysis - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued 1 year price targets for ProQR Therapeutics' stock. Their PRQR share price targets range from $1.80 to $5.00. On average, they expect the company's stock price to reach $3.80 in the next year. This suggests a possible upside of 67.4% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2024? ProQR Therapeutics' stock was trading at $1.98 at the start of the year. Since then, PRQR shares have increased by 14.6% and is now trading at $2.27. View the best growth stocks for 2024 here. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The biopharmaceutical company earned $3.54 million during the quarter, compared to analysts' expectations of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative trailing twelve-month return on equity of 56.71%. What ETF holds ProQR Therapeutics' stock? Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.04%), BNP Paribas Financial Markets (0.02%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRQR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.